Effects of UVA irradiation, aryl azides, and reactive oxygen species on the orthogonal inactivation of the human immunodeficiency virus (HIV-1)

Virology

Volumn 417, Issue 1, 2011, Pages 221-228

  Belanger, Julie M ^a   Raviv, Yossef ^b   Viard, Mathias ^b   de la Cruz, M Jason ^b,c   Nagashima, Kunio ^b   Blumenthal, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Azide; Detergent; HIV; Hydrophobic; Reactive oxygen species (ROS); Triton; Vaccine; Viral membrane

Indexed keywords

ARYL AZIDE DERIVATIVE; AZIDE; GAG PROTEIN; GLUTATHIONE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VIRUS VACCINE; REACTIVE OXYGEN METABOLITE; SUCROSE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN INTERACTION; TRANSMISSION ELECTRON MICROSCOPY; ULTRACENTRIFUGATION; ULTRAVIOLET A RADIATION; VIRUS INACTIVATION; VIRUS NEUTRALIZATION; WESTERN BLOTTING;

ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; AZIDES; HIV-1; NEUTRALIZATION TESTS; REACTIVE OXYGEN SPECIES; SOLUBILITY; ULTRAVIOLET RAYS; VIRUS INACTIVATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79960952999     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2011.06.007     Document Type: Article

References (26)

1. Adler-Storthz K., Sehulster L.M., Dreesman G.R., Hollinger F.B., Melnick J.L. Effect of alkaline glutaraldehyde on hepatitis B virus antigens. Eur. J. Clin. Microbiol. 1983, 2(4):316-320.
2. Bachmann M.F., Bast C., Hengartner H., Zinkernagel R.M. Immunogenicity of a viral model vaccine after different inactivation procedures. Med. Microbiol. Immunol. 1994, 183:95-104.
3. Belanger J.M., Raviv Y., Viard M., de la Cruz J.M., Nagashima K., Blumenthal R. Characterization of the effects of aryl-azido compounds and UVA irradiation on the viral proteins and infectivity of human immunodeficiency virus type 1. Photochem. Photobiol. 2010, 86(5):1099-1108.
4. Bercovici T., Gitler C. 5-[125I]Iodonaphthyl azide, a reagent to determine the penetration of proteins into the lipid bilayer of biological membranes. Biochemistry 1978, 17(8):1484-1489.
5. Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev. Biol. Stand. 1993, Vol. 81:103-107. Karger, Basel.
6. Brown F., Smale C.J., Horzinek M.C. Lipid and protein organization in vesicular stomatitis and sindbis viruses. J. Gen. Virol. 1974, 22:455-458.
7. Chertova E., Bess J.W., Crise B.J., Sowder R.C., Schaden T.M., Hilburn J.M., Hoxie J.A., Benveniste R.E., Lifson J.D., Henderson L.E., Arthur L.O. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type I and simian immunodeficiency virus. J. Virol. 2002, 76(11):5315-5325.
8. Coligan J.E. Commonly used detergents. Curr. Protoc. Immunol. 2001, A.1D.1-A.1D.3.
9. Cox R.J., Hovden A.-O., Brokstad K.A., Szysko E., Madhum A.S., Haaheim L.R. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine 2006, 24:6585-6587.
10. Duque H., Marshall R.L., Israel B.A., Letchworth G.J. Effects of formalin inactivation on bovine herpes virus-1 glycoprotein and antibody response elicited by formalin-inactivated vaccines in rabbits. Vaccine 1989, 7:513-520.
11. Geeraedts F., Bungener L., Pool J., ter Veer W., Wilschut J., Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respi. Viruses 2008, 2(2):41-51.
12. Greilberger J., Jurgens G. Oxidation of high-density lipoprotein HDL3 leads to exposure of apo-AI and apo-AII epitopes and to formation of aldehyde protein adducts, and influences binding of oxidized low-density lipoprotein to type I and type III collagen in vitro. Biochem. J. 1998, 331:185-191.
13. Grovit-Ferbas K., Hsu J.F., Ferbas J., Gudeman V., Chen I.S.Y. Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1. J. Virol. 2000, 74(13):5802-5809.
14. Jones O.T., Earnest J.P., McNamee M.G. Solubilization and reconstitution of membrane proteins. Biological Membranes: A Practical Approach 1987, IRL Press, Oxford. J. Findlay, W.H. Evans (Eds.).
15. Poon B., Safrit J.T., McClure H., Kitchen C., Hsu J.F., Gudeman V., Petropolous C., Wrin T., Chen I.S.Y., Grovit-Ferbas K. Induction of humoral immune response following vaccination with envelope-containing, formaldehyde-treated, thermally inactivated human immunodeficiency virus type 1. J. Virol. 2005, 79(8):4927-4935.
16. Raviv Y., Blumenthal R., Tompkins S.M., Humberd J., Hogan R.J., Viard M. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J. Virol. 2008, 82(9):4612-4619.
17. Raviv Y., Viard M., Bess J.W., Chertova E., Blumenthal R. Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J. Virol. 2005, 79(19):12394-12400.
18. Ruprecht C.R., Krarup A., Reynell L., Mann A.M., Brandenburg O.F., Berlinger L., Abela I.A., Regoes R.R., Gunthard H.F., Rusert P., Trkola A. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J. Exp. Med. 2011, 208(3):439-454.
19. Sattentau O.J. Conservation of HIV-1 gp120 neutralizing epitopes after formalin inactivation. AIDS 1995, 9:1383-1385.
20. Schultz A.M., Koff C.W., Lawrence D.N. Conference reports: workshop on HIV inactivated vaccines. Vaccine 1990, 8:516-517.
21. Sharma A., Raviv Y., Puri A., Viard M., Blumenthal R., Maheshwari R.K. Complete inactivation of Venezuelan equine encephalitis virus by 1,5-iodonaphthylazide. Biochem. Biophys. Res. Commun. 2007, 358:392-398.
22. Sheppard H.W. Inactivated- or killed-virus HIV/AIDS vaccines. Curr. Drug Targets Infect. Disord. 2005, 5:131-141.
23. Shoukry M.I., Gong E.L., Nichols A.V. Apolipoprotein-lipid association in oxidatively modified HDL and LDL. Biochim. Biophys. Acta 1994, 1210:355-360.
24. Tano Y., Shimizu H., Martin J., Nishimura Y., Simizu B., Miyamura T. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains. Vaccine 2007, 25:7041-7046.
25. Uchida E., Morimoto K., Kawasaki N., Izaki Y., Said A.A., Hayakawa T. Effect of active oxygen radicals on protein and carbohydrate moieties of recombinant human erythropoietin. Free Radic. Res. 1997, 27(3):311-323.
26. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Viard M., Aitichou M., Chi X., Ibrahim S., Blumenthal R., Raviv Y., Bavari S., Aman M.J. Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J. Infect. Dis. 2007, 196(2):S276-S283.